NextCure(US:NXTC)2025-11-05 21:16Financial Performance - NextCure reported a net loss of $8.6 million for Q3 2025, a decrease from a net loss of $11.5 million in Q3 2024, reflecting lower research and development and general administrative costs[9]. - Research and development expenses were $6.1 million for Q3 2025, down from $8.8 million in Q3 2024, primarily due to reduced costs related to deprioritized programs[9]. - General and administrative expenses were $2.8 million for Q3 2025, down from $3.7 million in Q3 2024, mainly due to lower personnel costs[9]. Cash and Assets - Cash, cash equivalents, and marketable securities decreased to $29.1 million as of September 30, 2025, from $68.6 million as of December 31, 2024, a decline of $39.5 million[9]. - Total assets decreased to $39.6 million as of September 30, 2025, from $80.9 million as of December 31, 2024[14]. - Total stockholders' equity fell to $23.6 million as of September 30, 2025, compared to $65.5 million as of December 31, 2024[14]. Future Outlook - The company expects its current financial resources to be sufficient to fund operations into mid-2026[9]. - Proof of concept data readouts for SIM0505 and LNCB74 are expected in the first half of 2026[2]. Clinical Development - NextCure initiated U.S. enrollment in the Phase 1 trial for SIM0505 in October 2025, with plans to advance into higher-dose cohorts shortly[2]. - The FDA accepted a protocol amendment for LNCB74, allowing the addition of higher dose escalation cohorts[9].